In GCs, androstenedione and testosterone act as substrates and are converted by CYP19A1 to estrogen, the mutation of CYP19A1 may lead to the occurrence and the development of hyperandrogenemia in PCOS (Kumariya et al., 2021). This evidence concerns the gene CYP19A1 and polycystic ovary syndrome.